Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
Completed
Johns Hopkins University
Phase 2
2010-11-01
The purpose of this study is to assess the comparative efficacy of retinol 1.0% and tretinoin
0.02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe
photodamage. Our hypothesis is that both products will be of comparable benefit.
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Recruiting
National Cancer Institute (NCI)
Phase 2
2011-10-05
This phase II trial studies how well tretinoin and arsenic trioxide with or without
gemtuzumab ozogamicin works in treating patients with previously untreated acute
promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as
gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal
cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill
more cancer cells.
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Recruiting
Pfizer
Phase 2
2011-10-05
This phase II trial studies how well tretinoin and arsenic trioxide with or without
gemtuzumab ozogamicin works in treating patients with previously untreated acute
promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as
gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal
cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill
more cancer cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.